Minisini Alessandro M, Andreetta Claudia, Fasola Gianpiero, Puglisi Fabio
University and General Hospital of Udine, Department of Oncology, Udine, Italy.
Expert Rev Anticancer Ther. 2008 Mar;8(3):331-42. doi: 10.1586/14737140.8.3.331.
Breast cancer incidence is increasing among elderly patients. Age is a risk factor for toxicity after chemotherapy for breast cancer. In particular, anthracycline-induced cardiac toxicity is increased in elderly patients. Novel liposomal anthracyclines are associated with less cardiotoxicity. Pegylated liposomal doxorubicin (PLD) is active in breast cancer patients and, has shown comparable efficacy to conventional doxorubicin in clinical trials. Most toxicities during PLD treatment are hematological and mucocutaneous (in particular stomatitis and palmo-plantar erythrodysesthesia), and cardiac toxicity is rare. Tolerability of this agent in elderly patients has been confirmed by clinical trials in the advanced disease. Due to its efficacy and safety profile, PLD is an appealing treatment option for elderly breast cancer patients.
老年患者的乳腺癌发病率正在上升。年龄是乳腺癌化疗后出现毒性反应的一个风险因素。特别是，老年患者中蒽环类药物引起的心脏毒性增加。新型脂质体蒽环类药物的心脏毒性较小。聚乙二醇化脂质体阿霉素（PLD）对乳腺癌患者有效，并且在临床试验中已显示出与传统阿霉素相当的疗效。PLD治疗期间的大多数毒性反应是血液学和黏膜皮肤方面的（尤其是口腔炎和手足红斑性感觉异常），心脏毒性罕见。晚期疾病的临床试验已证实该药物在老年患者中的耐受性。由于其疗效和安全性，PLD是老年乳腺癌患者有吸引力的治疗选择。
